Letters to the Editor

Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation

Pediatric Oncology, University Children’s Hospital Zurich, Zurich
The Kaiya Foundation for Children with Very High Risk Leukemia, London
Department of Pediatric Haemato-Oncology, IRCCS Ospedale Bambino Gesù, Roma, Catholic University of the Sacred Heart, Rome
Department of Haematology, Great Ormond Street Hospital, London
Department of Pediatric Hematology, Hôpital Robert Debré, Assistance Publique–Hôpitaux de Paris, Paris
Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel
Pediatric Hematology-Oncology, Schneider Children’s Medical Center, Sackler Faculty of Medicine, Aviv University
Department of Pediatric Oncology, Memorial Health Care, Private Medstar Yildiz Hospital, Antalya
Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg
Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel
Bone Marrow Transplant Unit, Schneider Children's Medical Center, Sackler Faculty of Medicine, Aviv University
Department of Pediatric Hematology, Medipol University Hospital, İstanbul
Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo
Department of Paediatric Haematology and Oncology, St. Olav's University Hospital, Trondheim
Department of Haematology, Great Ormond Street Hospital, London
University College London Hospitals NHS Foundation Trust, London
Department of Haematology, Great Ormond Street Hospital, London
Laboratory of Cytogenetics and Molecular Genetics, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel
School of Clinical Medicine, UNSW Sydney, Sydney, NSW, Australia; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW 2031
Clinic for Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf
Adolescent and Young Adult Hematology Unit, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris, Paris
Adolescent and Young Adult Hematology Unit, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris, Paris
Hematology Laboratory, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris, Paris
Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille
Department of Hematology, Saint Eloi hospital, Montpellier University Hospital, Montpellier
Department of Haematology, Sheffield Children’s Hospital, Sheffield
Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel
Department of Pediatric Oncology, Memorial Health Care, Private Medstar Yildiz Hospital, Antalya
Department of Pediatric Hematology, Hôpital Robert Debré, Assistance Publique–Hôpitaux de Paris, Paris
Department of Pediatric Haemato-Oncology, IRCCS Ospedale Bambino Gesù, Roma, Catholic University of the Sacred Heart, Rome
Pediatric Hematology and Oncology, Hannover Medical School, Hannover
Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin
Pediatric Oncology, University Children’s Hospital Zurich, Zurich
Pediatric Oncology, University Children’s Hospital Zurich, Zurich
Haematologica Early view Feb 6, 2025 https://doi.org/10.3324/haematol.2024.286111